Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop & Commercialize Next-Generation Cardiovascular...
April 16 2018 - 4:15PM
Business Wire
- Factor XIa inhibitor moving into
Phase 2 Trials for Secondary Stroke Prevention
- Bristol-Myers Squibb to receive
upfront payment and companies to share development and
commercialization costs, and global profits
Bristol-Myers Squibb Company (NYSE: BMY) today announced a
worldwide collaboration with Janssen Pharmaceuticals, Inc.
(Janssen) on a Factor XIa (FXIa) inhibitor program that includes
the development and commercialization of Bristol-Myers Squibb’s
Factor XIa (FXIa) inhibitor, BMS-986177, an investigational
anticoagulant compound being studied for prevention and treatment
of major thrombotic conditions. The companies are expected to
advance BMS-986177 into Phase 2 clinical trials in the second half
of 2018 for the study of secondary stroke prevention.
Thrombotic disorders include cardiovascular conditions such as
coronary artery disease, stroke and peripheral artery disease.
BMS-986177 is an inhibitor of Factor XIa, and is being explored for
its potential to improve upon the standard of care by reducing the
risk of vascular events – without increasing the risk of bleeding –
in patients with thrombotic disorders.
“At Bristol-Myers Squibb, we are rooted in our commitment to
patients with cardiovascular disease. We are proud to partner with
Janssen on our shared vision for advancing cutting-edge science to
develop potential new treatments such as BMS-986177 for serious
cardiovascular disease,” said Tom Lynch, M.D., executive vice
president and chief scientific officer, Bristol-Myers Squibb. “By
combining the strength of our companies’ extensive expertise in the
development and commercialization of cardiovascular treatments, we
can maximize the potential of FXIa inhibition.”
Bristol-Myers Squibb has a strong heritage of pioneering
research and advancing the development of novel compounds to
address areas of high unmet need for patients with serious
cardiovascular conditions. The collaboration will leverage both
companies’ resources and expertise to establish a broad development
program across multiple indications.
Janssen will pay Bristol-Myers Squibb an upfront sum along with
potential development and regulatory milestone payments. The
companies will share development costs and commercial profits and
losses. Additional terms of the agreement were not disclosed.
About Factor XIa
Factor XIa (FXIa) plays a key role in the activation and
amplification of the coagulation cascade via the intrinsic
pathway.i It was first noticed as a potential approach to
thrombosis because people with little or no FXIa (Hemophilia C)
show virtually no untoward bleeding in the absence of a major
injury or surgery. Further, a small study of Hemophilia C patients
showed a lower risk of stroke. Conversely, elevated levels of FXI
/FXIa are a risk factor for stroke and venous thromboembolism.
Preclinical and early clinical studies suggest that selectively
inhibiting the intrinsic branch of the coagulation cascade at an
upstream protease such as FXIa could be a key strategy to reducing
the risk of vascular events without increasing the risk of
bleeding.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb’s business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31,
2017 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
____________
i R. Al-Horani, et al. Factor XIa inhibitors: A review of patent
literature. Expert Opin Ther Pat. 2016; 26(3): 323-345.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180416005786/en/
Bristol-Myers SquibbMedia:Lisa McCormick Lavery,
609-252-7602lisa.mccormicklavery@bms.comorKen Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024